Cargando…
Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy
[Image: see text] [ZrO](2+)[(FCN)(0.4)(OH)(0.8)](2–) and Gd(3+)[FCN](3–) inorganic-organic hybrid nanoparticles (IOH-NPs) are novel saline antiviral nanocarriers with foscarnet (FCN) as a drug anion. FCN as a pyrophosphate analogue serves as a prototype of a viral DNA polymerase inhibitor. FCN is us...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007112/ https://www.ncbi.nlm.nih.gov/pubmed/35344659 http://dx.doi.org/10.1021/acsbiomaterials.2c00074 |
_version_ | 1784686792750923776 |
---|---|
author | Khorenko, Mikhail Rand, Ulfert Cicin-Sain, Luka Feldmann, Claus |
author_facet | Khorenko, Mikhail Rand, Ulfert Cicin-Sain, Luka Feldmann, Claus |
author_sort | Khorenko, Mikhail |
collection | PubMed |
description | [Image: see text] [ZrO](2+)[(FCN)(0.4)(OH)(0.8)](2–) and Gd(3+)[FCN](3–) inorganic-organic hybrid nanoparticles (IOH-NPs) are novel saline antiviral nanocarriers with foscarnet (FCN) as a drug anion. FCN as a pyrophosphate analogue serves as a prototype of a viral DNA polymerase inhibitor. FCN is used for the treatment of herpesvirus infections, including the drug-resistant cytomegalovirus (CMV) and herpes simplex viruses, HSV-1 and HSV-2. The novel [ZrO](2+)[(FCN)(0.4)(OH)(0.8)](2–) and Gd(3+)[FCN](3–) IOH-NPs are characterized by aqueous synthesis, small size (20–30 nm), low material complexity, high biocompatibility, and high drug load (up to 44 wt % FCN per nanoparticle). The antiviral activity of the FCN-type IOH-NPs is probed for the human cytomegalovirus (HCMV). Moreover, the uptake of FCN-type IOH-NPs into vesicles, cytoplasm, and nuclei of nonphagocytic lung epithelial cells is evaluated. As a result, a promising antiviral activity of the FCN-type IOH-NPs that significantly outperforms freely dissolved FCN at the level of clinical formulations is observed, encouraging a future use of FCN-type IOH-NPs for the delivery of antivirals against respiratory viruses. |
format | Online Article Text |
id | pubmed-9007112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-90071122023-03-28 Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy Khorenko, Mikhail Rand, Ulfert Cicin-Sain, Luka Feldmann, Claus ACS Biomater Sci Eng [Image: see text] [ZrO](2+)[(FCN)(0.4)(OH)(0.8)](2–) and Gd(3+)[FCN](3–) inorganic-organic hybrid nanoparticles (IOH-NPs) are novel saline antiviral nanocarriers with foscarnet (FCN) as a drug anion. FCN as a pyrophosphate analogue serves as a prototype of a viral DNA polymerase inhibitor. FCN is used for the treatment of herpesvirus infections, including the drug-resistant cytomegalovirus (CMV) and herpes simplex viruses, HSV-1 and HSV-2. The novel [ZrO](2+)[(FCN)(0.4)(OH)(0.8)](2–) and Gd(3+)[FCN](3–) IOH-NPs are characterized by aqueous synthesis, small size (20–30 nm), low material complexity, high biocompatibility, and high drug load (up to 44 wt % FCN per nanoparticle). The antiviral activity of the FCN-type IOH-NPs is probed for the human cytomegalovirus (HCMV). Moreover, the uptake of FCN-type IOH-NPs into vesicles, cytoplasm, and nuclei of nonphagocytic lung epithelial cells is evaluated. As a result, a promising antiviral activity of the FCN-type IOH-NPs that significantly outperforms freely dissolved FCN at the level of clinical formulations is observed, encouraging a future use of FCN-type IOH-NPs for the delivery of antivirals against respiratory viruses. American Chemical Society 2022-03-28 2022-04-11 /pmc/articles/PMC9007112/ /pubmed/35344659 http://dx.doi.org/10.1021/acsbiomaterials.2c00074 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Khorenko, Mikhail Rand, Ulfert Cicin-Sain, Luka Feldmann, Claus Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy |
title | Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles
for Effective Antiviral Therapy |
title_full | Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles
for Effective Antiviral Therapy |
title_fullStr | Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles
for Effective Antiviral Therapy |
title_full_unstemmed | Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles
for Effective Antiviral Therapy |
title_short | Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles
for Effective Antiviral Therapy |
title_sort | foscarnet-type inorganic-organic hybrid nanoparticles
for effective antiviral therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007112/ https://www.ncbi.nlm.nih.gov/pubmed/35344659 http://dx.doi.org/10.1021/acsbiomaterials.2c00074 |
work_keys_str_mv | AT khorenkomikhail foscarnettypeinorganicorganichybridnanoparticlesforeffectiveantiviraltherapy AT randulfert foscarnettypeinorganicorganichybridnanoparticlesforeffectiveantiviraltherapy AT cicinsainluka foscarnettypeinorganicorganichybridnanoparticlesforeffectiveantiviraltherapy AT feldmannclaus foscarnettypeinorganicorganichybridnanoparticlesforeffectiveantiviraltherapy |